Breaking Finance News

A statement released earlier today by Aegis about Kindred Biosciences Inc (NASDAQ:KIN) bumps the target price to $10.50

Boasting a price of $6.95, Kindred Biosciences Inc (NASDAQ:KIN) traded 0.68% higher on the day. With the last close down 2.18% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Kindred Biosciences Inc has recorded a 50-day average of $7.28 and a two hundred day average of $7.24. Volume of trade was down over the average, with 46,050 shares of KIN changing hands under the typical 234,344

Aegis increased the stock price target of Kindred Biosciences Inc (NASDAQ:KIN) to $10.50 stating a potential upside of 0.51%.

Performance Chart

Kindred Biosciences Inc (NASDAQ:KIN)

With a total market value of $0, Kindred Biosciences Inc has with a one year low of $3.90 and a one year high of $9.65 .

More About Kindred Biosciences Inc (NASDAQ:KIN)

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.